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ABSTRACT 
Liposomal chemotherapy offers several advantages over conventional therapies, including high 
intratumoral drug delivery, reduced side effects, prolonged circulation time and the possibility to 
dose higher. The efficient delivery of liposomal chemotherapeutics relies however on the 
enhanced permeability and retention (EPR) effect, which refers to the ability of macromolecules 
to extravasate leaky tumor vessels and accumulate in the tumor tissue. Using a panel of human 
xenograft tumors, we evaluated the influence of the EPR effect on liposomal distribution in vivo 
by injection of pegylated liposomes radiolabeled with 111In. Liposomal accumulation in tumors 
and organs was followed over time by SPECT/CT imaging. We observed that fast growing 
xenografts, which may be less representative of tumor development in patients, showed higher 
liposomal accumulation as compared to slow growing xenografts. Additionally, several other 
parameters determining the EPR effect were evaluated, such as blood and lymphatic vessel 
density, intratumoral hypoxia, and the presence of macrophages. The investigation of various 
parameters showed a few correlations. Although hypoxia, proliferation and macrophage presence 
were associated with tumor growth, no hard conclusions or predictions could be made regarding 
the EPR effect or liposomal uptake. However liposomal uptake was significantly correlated with 
tumor growth, with fast growing tumors showing a higher uptake, although no biological 
determinants could be elucidated to explain this correlation. 
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INTRODUCTION 
Almost all nanocarriers, including liposomes (1), and many other anti-cancer drugs rely on the 
enhanced permeability and retention (EPR) effect for accumulation in tumor tissue. The EPR 
effect is defined as the process of extravasation of large molecules from leaky tumor vasculature, 
leading to accumulation in tumor tissue (2). The EPR effect is dependent on many biological 
parameters, with the development of the abnormal tumor vasculature playing a major role, 
although other parameters such as the composition of the surrounding stroma, absence of 
functional lymphatics and presence of tumor infiltrating macrophages, also play an important role 
(3). Abnormally upregulated growth factors affect the vasculature of the tumor (4) and lead to 
large endothelial junctions at the luminal surface resulting in a leaky vasculature (5). In addition, 
vessels lack smooth muscle cell layers and supporting cells (6), and the fast recruitment of blood 
vessels results in tumor neovasculature that is not hierarchically organized causing a 
heterogeneous spatial distribution (4,7,8). Finally, tumors overexpress many permeability 
enhancing factors, which contribute to an enhanced EPR effect (9). These facts suggest that most 
tumors may be susceptible to nanoparticle treatment, but thus far such particles only show a 
limited effect in vivo due to various barriers such as the mononuclear phagocyte system, 
extracellular matrix, low pH, low oxygenation and high interstitial fluid pressure (10-12). The 
intra- and inter-tumoral heterogeneity are major factors influencing the EPR effect, especially in 
patients, which have a much slower tumor and vessel development (13). 
The FDA approved liposomal doxorubicin (Doxil or Caelyx) is one of the most succesful 
nanoparticle drugs for several cancer types (14-17). Unfortunately Doxil has a limited effect on 
overall survival when compared to conventional chemotherapy (3), as has been shown in various 
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clinical trials (17-19). This and previous results suggest that tumor physiology influences the 
efficacy of nanoparticle drugs, possibly due to variations in the EPR effect (20). 
Since the EPR effect is essential for the efficacy and mode of action of liposomes in vivo, the aim 
of this study was to investigate major parameters influencing EPR and their effects on liposomal 
uptake in tumor xenografts. To this end, we injected unloaded, long-circulating, pegylated Doxil-
like liposomes to determine liposomal tumor accumulation. Various human xenograft tumor 
models, including squamous cell carcinoma, breast cancer, and pancreatic cancer were selected 
based on tumor growth rate, taking into consideration that slow-growing tumors are more 
representative of tumor growth in patients. Our results show that it is difficult to elucidate single 
determinants of the EPR effect and we therefore suggest that liposomal uptake and distribution in 
tumors is a multifactorial process involving physiological and morphological parameters. 
MATERIAL AND METHODS 
Preparation of Unloaded Doxil Liposomes 
Doxil liposomes were prepared as described in the Supplemental Material and Methods.  
Cell Lines  
All cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA) 
and routinely cultured as described in Supplemental Material and Methods.  
111In Labeling of Liposomes 
Liposomes contained 0.1 mol% DTPA-PE lipid which enabled conjugation with 111InCl 
(Mallinckrodt Medical B.V., Petten, the Netherlands). 30 MBq 111In was incubated per µmol 
liposomes for 15 min at room temperature, 2.5 M Sodium acetate was used to set the pH at 5.0. 
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ITLC-SG (silica gel coated paper (Varian Inc.); 0.1 M Sodium citrate, mobile phase) was 
performed to ascertain complete labeling (21). Due to the molar excess of DTPA-lipid over 111In, 
lipid labeling efficiencies of > 99% was achieved. Prior to injections, the volume was adjusted to 
200 µL per µmol of liposomes with HEPES buffered saline (10 mM HEPES, 135 mM NaCl, pH 
7.4).  
In Vivo Biodistribution Studies 
Tumor inoculation of NMRI nu/nu mice is described in the Supplemental Material and Methods. 
Mice were injected i.v. (tail vein) with 1 µmol liposomes labeled with 111In. Immediately after 
injection, the animal was scanned (t = 0), using the following settings: SPECT (nanoSPECT/CT, 
Mediso Medical Imaging Systems) static scan with 20 projections, 60 seconds/projection, and a 
quality factor of 0.8. APT1 apertures were used with 1.4 mm diameter pinholes (FOV 24 + 16 
mm). CT scan: 240 projections, 45 kVp tube voltage and 500 ms exposure. The t = 0 scan was 
followed by scans at t = 4, 8, 12, and 24 h after injection. SPECT/CT analysis was performed 
using InVivoScope/VivoQuant software (inviCRO, Boston, MA). Three-dimensional regions of 
interest were drawn over the heart (blood pool) and tumor to calculate uptake of 111In-liposomes 
at the selected time points after which they were corrected for volume (%ID/cc). Representative 
figures were made with the same software after correction for 111In decay.  
Ex vivo biodistribution 
Tumors and tissue samples (blood (cardiac puncture), heart, lung, liver, spleen, pancreas, kidney, 
stomach, duodenum, caecum, colon, tail, and muscle) were harvested and weighed. Radioactivity 
was determined with a gamma counter (Perkin Elmer, Waltham, MA) and liposomal 
accumulation was calculated as percentage injected dose per gram of tissue (%ID/g) and 
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corrected for radioactive decay of 111In (t1/2 = 2.81 days). The injected dose was calculated by 
measuring the syringe before and after injection.  
Immunohistochemical Staining 
After the final scan, pimonidazole (60 mg/kg body weight) was injected i.p. and allowed to 
circulate for 4 h before dissection of tumor and organs. Harvested tumors were snap-frozen in 
liquid nitrogen and frozen tumor sections were used for immunohistochemical staining as 
described in Supplemental Material and Methods. Sections were stained for blood vessels 
(CD31), pegylated liposomes (PEG), macrophages (CD11b), lymphatic vessels (LYVE-1), vessel 
integrity (Collagen IV) and hypoxia (pimonidazole).  
Tile scans of fluorescently stained tumor sections were acquired using a Zeiss LSM 510 Meta 
confocal microscope (Carl Zeiss B.V., Sliedrecht, the Netherlands) with a Plan-Neofluar 10x 
objective. Quantifications were performed with ImageJ software, using manual thresholding 
(range 0-255) for density analysis and co-localization threshold tool to ascertain the ratio between 
PEG and CD31, and collagen IV and CD31. To avoid regional bias, all quantifications were 
performed on whole tile scans of tumor sections. 
Statistical Analysis 
Statistical analyses were performed using GraphPad Prism version 5.01 (GraphPad Software, San 
Diego, CA). Differences between fast, intermediate, and slow growing xenografts were evaluated 
using one-way ANOVA with non-parametric Kruskal–Wallis H test and Dunn’s multiple 
comparison post-test. Comparisons between the high and low uptake groups were performed 
using the two-tailed Mann-Whitney U test. Correlation analysis between the various parameters 
by Erasmus Universiteit on January 11, 2016. For personal use only. jnm.snmjournals.org Downloaded from 
Bolkestein et al.    Liposomal uptake and the EPR effect 
 
7 
 
evaluated in this study was performed using the Spearman’s rho test. All statistical tests were 
two-sided, and p value lower than 0.05 was considered statistically significant. 
 
RESULTS 
Characterization of Liposomes 
Liposomal characteristics, such as size and polydispersity were confirmed to be similar to Doxil 
and are described in detail in the Supplemental Results. 
To perform image-guided delivery, the liposomes were labeled with 111In for SPECT imaging. 
The radiolabeling efficiency with 111In after 15 min labeling at room temperature was > 99%. On 
average the liposomes were labeled with 34.54 ± 1.04 MBq 111In per µmol liposomes. 
Tumor Characterization 
Supplemental Results and Supplemental Figure 1 show the subdivision of tumor types based on 
growth rate. 
In Vivo Localization of 111In Labeled Liposomes in Human Tumor Xenografts 
All mice were injected i.v. with 1 µmol of liposomes labeled with 111In for SPECT imaging. 
Volume-of-interest (VOI) was drawn to quantify liposomal accumulation in tumor and heart. 
Figure 1A shows accumulation of liposomes in the tumor over time (t = 0, 4, 8, 12, 24 h post 
injection) as a percentage of injected dose corrected for tumor volume (%ID/cc). The EPR effect 
ensured accumulation of liposomes in the tumors over time, while the heart showed clearance of 
liposomes from circulation. In the heart, liposomes still account for 6.28 ± 1.50 %ID/cm3 (SD) 
after 24 h, which is confirmed by t½(β) of 16.99 ± 1.81 h (SEM). Figure 1B shows representative 
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mice depicting high liposomal uptake (HPAF-II tumor) and low liposomal uptake (PANC-1 
tumor). The SPECT-CT scans show radiolabeled liposomes in circulation, visible in the heart and 
aortic arch and aorta, and continuing downstream into axillary, hepatic, splenic, renal, and 
femoral arteries. The liposomes in circulation diminished over time and accumulated in liver, 
spleen and, to varying degrees, in the tumor. The liposomes are slowly cleared via the liver and 
spleen (mononuclear phagocytic system), while being retained in the tumor due to the EPR effect 
(22). Spleen macrophages and hepatic Kupfer cells can ingest liposomes and are responsible for 
liposome accumulation in these organs. Liver fenestrations (100 nm) and spleen lumina (up to 5 
µm) will further contribute to this accumulation (23).  
Supplemental Figure 2 shows all tumors 12 h after injection with radiolabeled liposomes. In 
addition to differences in total uptake, early variations in intratumoral localization were clearly 
visible and were probably caused by perfusion differences (24,25). For example, MDA-MB-231 
showed a clear uptake in certain regions of the tumor periphery, whereas other regions remained 
clear. Other tumors such as CFPAC-1 showed a more homogeneous distribution of liposomes. 
Importantly the circulation of liposomes and accumulation in liver and spleen were comparable 
between different tumor models, as confirmed by the biodistribution data. Liposomes are 
degraded in the liver after 12-24 h causing release of free 111In-DTPA. As detected by low levels 
of radioactivity in kidney and bladder, since free 111In -DTPA is rapidly cleared from circulation 
(26). 
Ex Vivo Organ Biodistribution 
Radioactivity uptake was measured after resection of the organs and other relevant tissues and is 
shown per tumor type in Figure 2, and in more detail for all analyzed organs, including the tumor, 
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in Supplemental Figure 3. The tumors are again arranged from fast to slow growing, with levels 
of uptake ranging from PANC-1 (1.51 ± 0.11 %ID/g) on the low end, to CFPAC-1 (7.99 ± 3.59 
%ID/g) on the high end. A trend was observed between tumor growth and liposomal uptake 
(Table 1, p = 0.0104), although outliers, such as A431, BxPC-3, and MDA-MB-468, indicate that 
other factors are important and may be influencing liposomal accumulation. The reason for this 
was investigated in more detail using immunohistochemical stainings (see below), but it is for 
example known that the presence of necrotic or poorly vascularized tumor cores in fast growing 
tumors may inhibit liposomal uptake (27). The majority of the liposomes accumulate in the liver, 
spleen, and tumor; after which they are cleared. Liposomal uptake in vivo was compared with 
other modalities used to detect liposomal uptake and the morphological parameters thought to 
influence the EPR effect and nanoparticle uptake. To this end, the tumors were subdivided in 
high and low uptake groups, the high uptake group included CFPAC-1, HPAF-II, and MDA-MB-
231 xenografts. Table 1 shows that the difference in uptake between these groups can be detected 
with all tested modalities: in vivo SPECT/CT imaging, ex vivo biodistribution, and the anti-PEG 
antibody staining (p values < 0.0001, < 0.0001, 0.0018, respectively). In addition, there was a 
significant difference in tumor growth, i.e. time required for the tumors to reach 200 mm3 (p = 
0.0104). We did not observe a statistically significant correlation with any other morphological 
parameter evaluated.  
Immunohistochemistry 
To further investigate the underlying mechanisms of the EPR effect and to find possible 
explanations for the observed variations in liposomal tumor uptake, several morphological 
parameters were investigated using immunohistochemistry. In Figure 3A, the percentage of total 
tumor areas positive for liposomal content was calculated using an anti-PEG antibody. This 
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shows a significant correlation with the in vivo and ex vivo quantifications (Supplemental Table 
2; p = 0.007 and p < 0.001, respectively). Additionally, the intratumoral localization of the 
liposomes was determined in relation to blood vessels (CD31) showing that the majority of 
liposomes had indeed extravasated from the vessels (Figure 3C), although the distance travelled 
from the vessels is minimal. The percentage of extravasated liposomes was calculated by 
subtracting the number of CD31-colocalized liposomes from the total number of liposomes 
present in the area. This is depicted in Figure 3D, where an example is given of a CD31 staining 
(green), total PEG staining (red) and the calculated colocalized liposomes (PEG in; yellow), 
which shows liposomes within and extravasated from these vessels (shown in PEG composite in 
yellow and red respectively). Figure 3B shows HPAF-II and PANC-1 frames to demonstrate the 
difference of liposome localization in tumors with high and low uptake, respectively. Although 
nanoparticle distribution and accumulation is undeniably related to the presence of blood vessels 
(28), Figure 4A shows that the number of vessels (depicted in percentage Mean Vessel Density) 
cannot be used to predict the degree of liposomal uptake. For example, AsPC-1 and UACC-893 
have a similar uptake of liposomes, depicted with in vivo, ex vivo, and immunohistochemical 
quantifications, but the mean vessel density of UACC-893 is three times higher than that of 
AsPC-1 (Supplemental Figure 4A). As mentioned before, the factors influencing the EPR effect 
and the uptake of liposomes are more complex. The mononuclear phagocytic system (MPS) also 
has a major influence on the delivery of liposomes, although detection by the MPS may be 
reduced by pegylation (29,30). Monocytes internalize liposomes, after which the drug may be 
released, resulting in toxic effects to the monocytes. Figure 4B shows that the percentage of 
macrophages in the tumor tissue is in general relatively low, with the exception of MDA-MB-468 
(5.70 ± 2.26 %). This might explain why a slow growing tumor (5 months) with a poor mean 
vessel density (1.79 ± 0.42 %) still has a considerable liposomal uptake (2.87 ± 1.05 %). Hypoxia 
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is usually correlated with poor vascularization and indicative of poor drug uptake. Due to 
unrestrained tumor growth, cells move beyond the distance over which oxygen can diffuse (circa 
150 µm) and drugs targeting fast dividing cells will usually be less effective (31,32). All tumors 
show a comparable degree of hypoxia (Figure 4C), suggesting that this aspect plays a minor role 
in these tumor models. The functionality of both blood and lymphatic vessels is thought to be of 
great importance to the EPR effect and eventual uptake of macromolecules (2). We therefore 
incorporated a lymphatic marker (LYVE-1) and a collagen IV antibody to measure lymphatic 
vessel density and collagen IV support of blood vessels. The lymphatic vessels (Figure 5A and 
5B) are important for drainage of the tissue and the result suggests that high presence of these 
vessels caused lower uptake in BxPC-3 tumors. The intermediate growing BxPC-3 has a high 
lymphatic vessel density, 1.52 ± 0.86 %, a lymphatic-to-blood vessel ratio of 0.35 ± 0.11 with a 
well-developed mean vessel density, 5.19 ± 0.92 %, and still showed a relatively poor liposomal 
accumulation. In addition BxPC-3 tumor cells grew in tight clusters which may be an additional 
factor contributing to the lower uptake, because the tissue is less permeable to liposomes. Most 
tumors have blood vessels supported with collagen IV matrix, apart from MDA-MB-468 tumors 
(Figure 5C and 5D). In order to decipher possible associations between liposomal uptake and the 
various morphological parameters tested, we performed a correlation analysis (Supplemental 
Table 2). Although there was a significant correlation between the percentage PEG and the 
liposomal uptake in vivo, no further significant correlations related to other tested morphological 
parameters could be found. A multivariate analysis requiring a much larger data set may in future 
show whether multiple parameters are responsible.  
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DISCUSSION 
The EPR effect, first described by Matsumura and Maeda in 1986 (2), shows tumor-specific 
accumulation of large molecules, dependent on the following parameters: the size of the 
molecule(s) should be larger than the renal clearance threshold (7 nm) to prevent fast clearance; 
the molecule should have characteristics that ensure a long circulation time to increase the chance 
for extravasation; and the nature of the tumor has to be such that it will ensure retention of these 
molecules, usually ranging from days to weeks, leading to enhanced efficacy. These properties 
distinguish the EPR effect needed for therapeutic purposes from targeting of low-molecular 
weight molecules with a short half-life and fast clearance, which are more suited for imaging 
purposes (33). By utilizing the EPR effect, pegylated liposomes such as Doxil, have been 
successful in the treatment of certain cancers.  
This study has consolidated that pegylated liposomes can accumulate in various solid tumors, 
although considerable differences in uptake were observed. Uptake levels ranged from PANC-1 
to CFPAC-1 at the low to high end, respectively. There is a trend between liposome accumulation 
and the speed of tumor growth. Tumors, such as squamous cell carcinoma A431, showed very 
fast tumor growth, but had limited liposomal accumulation in the tumor. This could be explained 
by the high growth rate and relatively large size of these tumors. Angiogenesis is increased 
during tumor growth (34) and the tumor will grow exponentially until sufficient vascularization 
can no longer be sustained. This leads to hypoxic or necrotic tumor cores, which are more 
difficult to reach with anti-cancer drugs. Before this point is reached, the chaotic development of 
tumor vasculature together with the obstruction and collapse of lymphatic vessels at the tumor 
core will lead to an enhanced EPR effect and possibly an increased accumulation of nanoparticles 
(2). Lymphatic vessel density evaluation revealed that most tumors had an impaired lymphatic 
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system aiding liposome accumulation. The exception was the intermediate growing BxPC-3 
which had a high lymphatic vessel density and a well-developed mean vessel density, although it 
still showed a relatively poor liposomal accumulation. Although it has been hypothesized that 
normalizing the vasculature, extracellular matrix and lymphatic vessels would lead to better 
delivery of drugs (35), this may therefore not always hold true for liposomal drugs. 
Normalization of vessels will lead to a less leaky vasculature, which might impair the EPR effect. 
It has also been shown that mean vessel density correlates with the degree of liposome 
accumulation (28), but we did not observe this correlation in our study. The liposomes were still 
in circulation after 24 h. Various degrees of colocalization of blood vessels and liposomes was 
observed, but the majority of liposomes had extravasated from tumor vessels. Unfortunately high 
levels of extravasation do not always result in high efficacy, due to poor penetration 
characteristics of liposomes. The liposomes did not penetrate further than the perivascular space, 
confirming that smaller particles (12 nm) can penetrate a tumor heterogeneously up to 80 µm, but 
particles of 60 nm and larger do not leave the perivascular space or even the vessel (36). Several 
additional barriers like high interstitial fluid pressure, low oxygenation, and the extra-cellular 
matrix need to be overcome (12). 
Various other variables can influence the uptake of liposomes and the EPR effect in addition to 
the important role of the vasculature. For example, associated inflammation (37) and interactions 
with monocytes (38) can play a major role to increase the liposomal uptake in the tumor. This 
may explain why MDA-MB-468 had an intermediate liposomal uptake even though the mean 
vessel density was low. The monocyte staining to determine the involvement of the immune 
system showed a high presence of macrophages in MDA-MB-468 as opposed to the other 
tumors.  
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This study supports the notion that the EPR effect is a highly complex, multifactorial, 
heterogeneous phenomenon, possibly much larger in animal tumors than in patients (13). Due to 
tumors usually growing faster in animal models, it is to be expected that they will have a higher 
degree of vascularization and a lesser developed vascular environment, leading to a high EPR 
effect. For this reason we also investigated slow growing tumors with a lower vessel density to 
investigate pegylated liposomes in a more clinically relevant setting. Especially the pancreatic 
tumor models are more representative for the clinical setting, where human tumors grow over 
long periods of time (39). Slow growing tumors, such as prostate and pancreatic tumors are 
known to have more normalized vessels and are usually difficult to treat with nanomedicine. Here 
we show that even within the pancreatic tumor models, there is a wide range in liposome uptake 
and EPR effect, which accentuates the importance of selecting the appropriate tumor model(s) for 
preclinical studies. In addition, it is crucial to include an imaging modality in studies 
investigating the effects of nanoparticle accumulation in vivo and to intervene if the therapy is 
inhibited by poor access to the tumor. Fortunately, an increasing number of methods to enhance 
the EPR effect in tumors have been developed, both in preclinical and clinical settings, including 
the use of heat to increase vessel permeability and induce extravasation of nanomedicine (40-43).  
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FIGURE 1. 
A. Average tumor uptake in percentage injected dose per cubic centimeter tumor (%ID/cc) was 
calculated and is depicted at t = 0, 4, 8, 12, and 24 h post injection. B. Representative SPECT/CT 
scans, adjusted for 111In half-life, of HPAF-II or PANC-1 tumor (white circle) bearing mice at 
different time intervals after injection with 111In-labeled liposomes showing uptake of liposomes 
over time to a higher (HPAF-II) and lesser (PANC-1) degree. 
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FIGURE 2. 
Tumor liposome accumulation of 111In in percentage injected dose per gram at 24 h after i.v. 
injection (%ID/g tumor) ordered from fast to slow growing tumor xenografts. 
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FIGURE 3. 
A. Percentage of liposome uptake calculated from immunohistochemical staining of PEG, which 
shows a comparable uptake as in vivo/ex vivo quantifications. B. Representative images of tumor 
periphery and center indicate that uptake in the periphery is higher in both high and low uptake 
tumors. C/D. Extravasated liposomes calculated for all tumors based on the total PEG (red) 
minus PEG colocalized (yellow) with blood vessels (CD31, green), leading to a final composite 
figure showing the colocalized (yellow) and extravasated (red) liposomes. The degree of 
extravasation is relatively high in all tumors. All quantifications were performed on whole tile 
scans of the tumorsections. Scale bars, 100 µm. 
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FIGURE 4. 
A. Mean vessel density (MVD) in tumors based on anti-CD31 staining. B. Macrophages are 
stained with anti-CD11b antibody and a high number is seen in MDA-MB-468 tumors. C. 
Hypoxia percentage in different tumors which was calculated based on the presence of 
pimonidazole after i.p. injection. The degree of hypoxia is comparable for all tumors. All 
quantifications were performed on whole tile scans of the tumor sections. 
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FIGURE 5 
A. LYVE-1 staining indicates the presence of lymphatic vessels in the different tumors, which 
can be used to interpret possible drainage of the tumor. B. Lymphatic vessel (LYVE-1) to blood 
vessel (CD31) ratio, indicative of the supply and drainage of tumor tissue. C. Collagen IV is 
important for the support of blood vessels and is used as a marker for healthy blood vessels. The 
degree of collagen is comparable between tumors. D. Colocalization of collagen IV and blood 
vessels (CD31) supports the observation that most tumor vessels are mature and supported by 
collagen, with the exception of MDA-MB-468. All quantifications were performed on whole tile 
scans of the tumor sections. 
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TABLE 1. 
Characteristics (median, IQR) High uptake (n = 9) Low uptake (n = 17) p value 
Liposomal uptake    
  Liposomes (in vivo) 4.16 (3.67 - 5.01) 2.12 (1.50 - 2.45) < 0.0001* 
  Liposomes (ex vivo) 4.24 (3.95 - 7.06) 2.26 (1.76 - 2.62) < 0.0001* 
Time in days 25 (21 - 43) 70 (52 - 79)  0.0104* 
Morphological parameters    
  PEG percentage 5.64 (4.92 - 11.77) 2.50 (0.97 - 4.07)  0.0018* 
  CD31 percentage 2.84 (2.08 - 3.98) 2.87 (2.12 - 5.57) 0.5899 
  Pimonidazole percentage 37.13 (24.12 - 40.72) 33.49 (27.23 - 45.19) 0.6276 
  Ki67 percentage 7.63 (5.32 - 9.21) 7.79 (5.52 - 11.39) 0.4188 
  LYVE-1 percentage 0.37 (0.15 - 0.79) 0.21 (0.06 - 0.41) 0.2465 
  CD11b percentage 1.01 (0.31 - 2.26) 1.40 (0.39 - 2.53) 0.4834 
  Collagen percentage 18.56 (12.23 - 20.23) 13.72 (8.31 - 16.46) 0.0524 
 
Abbreviation: IQR = inter quartile range 
Statistical test used: two-tailed Mann-Whitney U test 
* significant at p < 0.05 level 
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